Aclarion’s augmented intelligence tool, Nociscan, is more cost effective compared to provocative discography, according to a new study.
The study, published in Clinicoeconomics and Outcomes Research, assessed data from 139 chronic lower back pain patients. The mean total cost for patients using provocative discography diagnostics was $59,711 and $57,998 using Aclarion’s magnetic resonance spectroscopy (Nociscan), showing savings of $1,712 per patient.
The study also showed a 10% improvement in surgical success for Nociscan patients compared to provocative discography patients.
“We believe the results demonstrating Nociscan’s economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend, in other words, the value in healthcare,” Ryan Bond, chief strategy officer at Aclarion, said in an April 21 news release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.